Found 1 clinical trials
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2
squamous non-small cell lung cancer
lung carcinoma
measurable disease
systemic therapy
cancer chemotherapy
- 0 views
- 15 May, 2022
- 1 location